Estimated Cumulative Incidences of Primary and Secondary Event-Based Outcomes as a Function of Time From Baseline
death, prostate cancer
PROSTATE CANCER
Aalen-Johansen estimates of cumulative incidence with death as a competing risk, together with pointwise 95% CIs, are shown. Hazard ratios (HRs) and associated 95% CIs and The number of participants with any prostate cancer did not differ between the TRT (12 [0.46%]) and placebo (11 [0.42%]) groups (HR, 1.07; 95% CI, 0.47-2.42; 